Digestive Healthcare Center News
Aspirin therapy's ability to reduce the risk of colorectal cancer, an association seen in a large number of studies, appears to depend on the drug's inhibition of the COX-2 enzyme, the action that also underlies aspirin's usefulness for treating pain and inflammation.
Study reveals aspirin's colorectal cancer prevention mechanism
Prevention restricted to tumors expressing COX-2, may help identify those most likely to benefit
23/May/2007
BOSTON - May 23, 2007 - Aspirin therapy's ability to reduce the risk of colorectal cancer, an association seen in a large number of studies, appears to depend on the drug's inhibition of the COX-2 enzyme, the action that also underlies aspirin's usefulness for treating pain and inflammation. In the May 24 New England Journal of Medicine, investigators from Massachusetts General Hospital, Dana-Farber Cancer Institute and Brigham and Women's Hospital report that regular aspirin intake only reduced the incidence of colorectal tumors that overexpress COX-2.
"We knew that aspirin can block COX-2 function and that COX-2 is present in the vast majority of colorectal tumors but not in normal colon tissue," explains Andrew Chan, MD, MPH, of Mass General's Gastroenterology Division , the paper's lead author. "Therefore we hypothesized that, if blocking the COX-2 pathway was the mechanism underlying aspirin-associated risk reduction, it should preferentially reduce the incidence of those tumors that rely on COX-2."
To investigate that theory, the research team compiled data from two ongoing prospective research studies - the Nurses Health Study (NHS) and the Health Professionals Follow-up Study (HPFS). Both studies gather comprehensive health information on their participants every two years, data which is analyzed for associations between factors such as diet and the incidence of several diseases. Both the NHS, which enrolls more than 120,000 female registered nurses, and the HPFS, following more than 50,000 men employed in the health professions, have previously found associations between aspirin intake and reduced colorectal cancer risk.
For the current study, the researchers focused on almost 83,000 NHS participants and about 47,000 HPFS participants for whom necessary information was available. They received permission to acquire medical records and pathology reports from those who had reported being diagnosed with colorectal cancer, then retrieved more than 600 pathology specimens from participants whose diagnoses could be confirmed. The samples were analyzed for expression of COX-2.
As seen in previous reports, among the more than 120,000 participants, those who took at least two standard aspirin tablets a week had about three-quarters the risk of colorectal cancer that aspirin non-users did. However, analysis of tumor samples showed that reduction in risk only applied to tumors that expressed COX-2. The incidence of COX-2-negative tumors was virtually the same among those who did and did not take aspirin.
"These results will allow us to test another hypothesis: that in patients who have had colorectal cancer or polyps in the past, expression of COX-2 in the earlier lesion might indicate those for whom aspirin could reduce the risk of recurrence," says Charles Fuchs, MD, MPH, of Dana-Farber, the study's senior author. "Answering that will be our next target."
Both researchers note that current evidence does not support generally recommending aspirin therapy to reduce colorectal cancer risk. "For most people, the best way to prevent colorectal cancer is through screening, which we know saves lives by allowing us to treat polyps before they become cancers," says Chan.
Fuchs adds, "An individual who has had colorectal cancer in the past is at higher risk for subsequent tumors, and that might be someone who should discuss the advisability of taking aspirin with his or her primary care physician. We hope that our future research will further clarify who would benefit most from regular aspirin therapy and that understanding the mechanism of this effect will lead to new preventive and treatment strategies."
Fuchs is an associate professor of Medicine at Harvard Medical School, where Chan is an assistant professor of Medicine. Study co-author Shuji Ogino, MD, PhD, is an HMS assistant professor of Pathology at Brigham and Women's Hospital. The study was supported by grants from the National Cancer Institute, the National Institutes of Health, the Bennett Family Fund for Targeted Therapies Research, the Entertainment Industry Foundation National Colorectal Cancer Research Alliance, the Marshall S. Kates Memorial Fund, and the Foundation for Digestive Health and Nutrition.
Massachusetts General Hospital is the original and largest teaching hospital of Harvard Medical School. Mass General conducts the largest hospital-based research program in the United States, with major research centers in AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, human genetics, medical imaging, neurodegenerative disorders, regenerative medicine, systems biology and physiologic genomics, transplantation biology, and photomedicine.
Dana-Farber Cancer Institute is a principal teaching affiliate of the Harvard Medical School and is among the leading cancer research and care centers in the United States. It is a founding member of the Dana-Farber/Harvard Cancer Center (DF/HCC), a designated comprehensive cancer center by the National Cancer Institute.
Media Contact: Sue McGreevey, MGH Public Affairs
William Schaller, DFCI Public Affairs
Award-winning medical care 
Massachusetts General Hospital is recognized as a leader in patient care, education and research, ranking among the most prestigious medical institutions.
